Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Jul 2019

At a glance

  • Drugs Sarizotan (Primary)
  • Indications Rett syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms STARS
  • Sponsors Newron Pharmaceuticals
  • Most Recent Events

    • 01 Feb 2019 According to a Newron Pharmaceuticals media release, data from this study were presented at the R&D day on 31 Oct 2018.
    • 01 Feb 2019 Results presented in a Newron Pharmaceuticals media release.
    • 01 Feb 2019 According to a Newron Pharmaceuticals media release, based on the results from this study , if positive, the company will submit a filing for marketing authorization with the US, Canadian and European regulatory agencies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top